Gerlinde Wernig

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4870705/publications.pdf

Version: 2024-02-01

32 papers	7,236 citations	377584 21 h-index	511568 30 g-index
35 all docs	35 docs citations	35 times ranked	7888 citing authors

#	Article	IF	Citations
1	Preventing Engrailed-1 activation in fibroblasts yields wound regeneration without scarring. Science, 2021, 372, .	6.0	269
2	JUN promotes hypertrophic skin scarring via CD36 in preclinical in vitro and in vivo models. Science Translational Medicine, 2021, 13, eabb3312.	5.8	32
3	Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	24
4	Integrated spatial multiomics reveals fibroblast fate during tissue repair. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	76
5	NK cell receptor and ligand composition influences the clearance of SARS-CoV-2. Journal of Clinical Investigation, 2021, 131, .	3.9	26
6	Selective Targeting of Immune Modulatory Proteins to Mitigate Fibrosis and Inflammation in Sclerodermatous Graft-Vs-Host Disease. Blood, 2021, 138, 644-644.	0.6	0
7	Doxycycline Reduces Scar Thickness and Improves Collagen Architecture. Annals of Surgery, 2020, 272, 183-193.	2.1	22
8	Elucidating the fundamental fibrotic processes driving abdominal adhesion formation. Nature Communications, 2020, 11, 4061.	5.8	52
9	Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity. Nature Communications, 2020, 11, 2795.	5.8	69
10	Expansion of Bone Precursors through Jun as a Novel Treatment for Osteoporosis-Associated Fractures. Stem Cell Reports, 2020, 14, 603-613.	2.3	16
11	CD47 prevents the elimination of diseased fibroblasts in scleroderma. JCI Insight, 2020, 5, .	2.3	25
12	Modeling Chronic Graft-versus-Host Disease in MHC-Matched Mouse Strains: Genetics, Graft Composition, and Tissue Targets. Biology of Blood and Marrow Transplantation, 2019, 25, 2338-2349.	2.0	11
13	Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nature Communications, 2019, 10, 617.	5.8	130
14	Direct targeting of the mouse optic nerve for therapeutic delivery. Journal of Neuroscience Methods, 2019, 313, 1-5.	1.3	9
15	Surgical adhesions in mice are derived from mesothelial cells and can be targeted by antibodies against mesothelial markers. Science Translational Medicine, 2018, 10, .	5.8	70
16	Unifying mechanism for different fibrotic diseases. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4757-4762.	3.3	155
17	Mapping the Pairwise Choices Leading from Pluripotency to Human Bone, Heart, and Other Mesoderm Cell Types. Cell, 2016, 166, 451-467.	13.5	367
18	Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands. Cell, 2015, 160, 1196-1208.	13.5	138

#	Article	IF	Citations
19	Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells. Cancer Cell, 2010, 17, 584-596.	7.7	324
20	Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera. Cancer Cell, 2008, 13, 311-320.	7.7	356
21	High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood, 2008, 111, 4788-4796.	0.6	84
22	The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood, 2008, 111, 3751-3759.	0.6	122
23	EXEL-8232, a Small Molecule JAK2 Inhibitor, Effectively Treats Thrombocytosis and Extramedullary Hematopoiesis in a Murine Model of Myeloproliferative Disease Induced by MPLW515L. Blood, 2008, 112, 3741-3741.	0.6	0
24	High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia.. Blood, 2007, 110, 886-886.	0.6	3
25	Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.. Blood, 2007, 110, 556-556.	0.6	2
26	Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders. Hematology American Society of Hematology Education Program, 2006, 2006, 233-239.	0.9	54
27	Expression of Jak2V617F causes a polycythemia veraâ€“like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood, 2006, 107, 4274-4281.	0.6	448
28	JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood, 2006, 108, 2770-2779.	0.6	104
29	MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Medicine, 2006, 3, e270.	3.9	1,222
30	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7, 387-397.	7.7	2,695
31	Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18962-18967.	3.3	288
32	The vast majority of bone-marrow-derived cells integrated into mdx muscle fibers are silent despite long-term engraftment. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11852-11857.	3.3	41